Vyepti™ (eptinezumab-jjmr) is a drug approved for the preventive treatment (long-term treatment) of migraine in adults. Vyepti is given intravenously (IV) once every several months. It is not meant for the acute treatment (or fast-acting treatment) of migraine.
What are the ingredients in Vyepti?
The active ingredient in Vyepti is eptinezumab-jjmr. Eptinezumab-jjmr is a calcitonin gene-related peptide (CGRP) antagonist. It belongs to a class of drugs called monoclonal antibodies.
How does Vyepti work?
Drugs that are monoclonal antibodies, like Vyepti, are made from living cells and have very specific targets in the body. Vyepti targets and blocks CGRP in the brain and some of the sensory nerves of the head and neck (called the trigeminal system). CGRP is a protein found in these areas that transmits pain signals. During a migraine attack, people often have high levels of CGRP, which may contribute to their severe symptoms. By blocking CGRP, migraine pain may be reduced.
What are the possible side effects of Vyepti?
The most common side effects reported with Vyepti are allergic reactions and upper respiratory infections. Signs of an allergic reaction include rash, shortness of breath, hives, and swelling of the mouth, face or throat. If you think you are experiencing an allergic reaction to Vyepti, contact your doctor immediately.
These are not all the possible side effects of Vyepti. Patients should talk to their doctor about what to expect with treatment with Vyepti.
Things to know about Vyepti
Before starting Vyepti, tell your healthcare provider about any other medicines you are taking. This includes over-the-counter drugs, supplements, and vitamins.
It is not known how Vyepti might affect an unborn baby. If you or your partner could become pregnant while taking Vyepti, tell your doctor. Women who are breastfeeding or plan to breastfeed should also talk to their doctor before starting Vyepti. Vyepti should only be used by adults at this time.
For more information, read the full prescribing information of Vyepti.